Johnson & Johnson stands alone as a leader across the major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a wide economic moat.
The majority of J&J's near-term patent losses are for products that are hard to manufacture, which should reduce the intensity of generic competition.
J&J's late-stage drug pipeline is relatively weak for the size of the company, which could create long-term headwinds for growth.
|
Metric
|
JNJ
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.75 | 86.35 | 59.67 |
Price/Book Value | 5.30 | 59.89 | 8.13 |
Price/Sales | 4.33 | 20.30 | 5.37 |
Price/Cash Flow | 16.67 | 84.37 | 18.88 |
|
Metric
|
JNJ
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.84 | 0.68 | 0.68 |
Current Ratio | 1.17 | 1.35 | 1.25 |
Interest Coverage | 23.57 | 14.11 | 3.97 |
|
Metric
|
JNJ
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 12.64% | 11.20% | 5.22% |
Return on Equity (Normalized) | 31.72% | 57.69% | 13.56% |
Return on Invested Capital (Normalized) | 20.11% | 20.65% | 8.29% |
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Bsqvwlrfk | Scn | $768.4 Bil | |
MRK
| Merck & Co Inc | Tsbkqzstf | Qhpq | $332.0 Bil | |
ABBV
| AbbVie Inc | Qnvqvtdj | Smxp | $277.3 Bil | |
AZN
| AstraZeneca PLC ADR | Zdcthqkdqt | Xsybg | $244.6 Bil | |
RHHBY
| Roche Holding AG ADR | Mjdgzwhfk | Mhvjl | $204.8 Bil | |
NVS
| Novartis AG ADR | Qwmsbvyjc | Bdkp | $204.7 Bil | |
AMGN
| Amgen Inc | Zyhrjwcph | Wdfn | $164.1 Bil | |
PFE
| Pfizer Inc | Bbjjqlmm | Jhjb | $163.7 Bil | |
SNY
| Sanofi SA ADR | Rlmpsts | Jjwt | $122.0 Bil |
:quality(80)/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)